Trial Profile
A 8-week, randomized, open-label, parallel, active-controlled study to evaluate intraocular pressure-reducing effects of latanoprost versus timolol in chinese patients with chronic angle-closure glaucoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Latanoprost (Primary) ; Timolol
- Indications Angle-closure glaucoma
- Focus Therapeutic Use
- 06 Dec 2015 New trial record